This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Celgene's Robert J. Hugin Becomes PhRMA Board Chairman; Ian C. Read, Kenneth C. Frazier Assume New Posts

Mr. Read is the chairman and CEO of Pfizer. He began his career with Pfizer in 1978 as an operational auditor. Mr. Read worked in Latin America through 1995, holding positions in a number of Pfizer's international operations. In 1996, he was appointed president of Pfizer's International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became executive vice president, Europe in 2000, and was named a corporate vice president in 2001. In 2006, he became senior vice president, Pfizer, and group president of the Worldwide Biopharmaceutical Businesses.

"The biopharmaceutical industry's efforts to discover and develop innovative new medicines not only has a significant impact in saving and improving lives, but is also an essential driver of the broader economy," Mr. Read said. "PhRMA is committed to working with policymakers, elected officials and our members to develop the right policy framework that supports innovation that results in creating value for society by enhancing productivity and improving the quality of life globally."

Mr. Frazier is chairman, president and CEO of Merck & Co. Previously, he served as president of Merck with responsibility for the company's three major divisions: Global Human Health, Merck's sales and marketing division for pharmaceutical and vaccine products; Merck Manufacturing, the company's manufacturing and supply division; and Merck Research Laboratories, Merck's research organization. Mr. Frazier received his bachelor's degree from The Pennsylvania State University and holds a J.D. from Harvard Law School.

"Congratulations to my colleagues who have made many outstanding contributions to healthcare and our industry through their work with PhRMA. I look forward to continuing my work with PhRMA to ensure that patients and caregivers benefit from the many scientific advances that the pharmaceutical industry has to offer," said Mr. Frazier.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,203.37 -85.26 -0.47%
S&P 500 2,107.78 -9.61 -0.45%
NASDAQ 4,979.9010 -28.1950 -0.56%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs